Wuhan YZY Biopharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	145	107.81	-	-	-
Other Revenue	4.35	-	-	2.28	12.16
Revenue	149.35	107.81	-	2.28	12.16
Revenue Growth (YoY)	-	-	-	-81.28%	-
Cost of Revenue	52.26	22.74	-	-	-
Gross Profit	97.08	85.07	-	2.28	12.16
Selling, General & Admin	25.62	26.59	22.31	20.53	31.5
Research & Development	154.88	164.99	155.05	157.33	112.89
Other Operating Expenses	-8.53	-8.53	-11.97	-	-
Operating Expenses	171.97	183.05	165.4	177.85	144.39
Operating Income	-74.88	-97.98	-165.4	-175.58	-132.23
Interest Expense	-4.43	-4.08	-2.39	-2.47	-14.97
Interest & Investment Income	1.12	2.57	1.05	0.28	0.16
Currency Exchange Gain (Loss)	0.24	1.95	-1.92	-	-
Other Non Operating Income (Expenses)	-	-	-24.63	-11.77	-2.67
EBT Excluding Unusual Items	-77.96	-97.54	-193.29	-189.53	-149.71
Gain (Loss) on Sale of Investments	-	-	1.61	0.67	1.26
Gain (Loss) on Sale of Assets	-0.08	-0.07	-0.02	-0	-0.55
Other Unusual Items	-	0.01	-	-	0.47
Pretax Income	-78.04	-97.6	-191.7	-188.87	-148.52
Net Income	-78.04	-97.6	-191.7	-188.87	-148.52
Net Income to Common	-78.04	-97.6	-191.7	-188.87	-148.52
Shares Outstanding (Basic)	194	194	185	172	152
Shares Outstanding (Diluted)	194	194	185	172	152
Shares Change (YoY)	1.47%	4.72%	7.60%	13.10%	-
EPS (Basic)	-0.40	-0.50	-1.04	-1.10	-0.98
EPS (Diluted)	-0.40	-0.50	-1.04	-1.10	-0.98
Free Cash Flow	-31.12	-102.22	-187.95	-178.11	-100.61
Free Cash Flow Per Share	-0.16	-0.53	-1.01	-1.03	-0.66
Gross Margin	65.01%	78.90%	-	100.00%	100.00%
Operating Margin	-50.14%	-90.88%	-	-7710.89%	-1087.03%
Profit Margin	-52.25%	-90.53%	-	-8294.51%	-1220.96%
Free Cash Flow Margin	-20.83%	-94.81%	-	-7822.31%	-827.14%
EBITDA	-70.08	-92.01	-158.99	-169.23	-125.2
EBITDA Margin	-46.92%	-85.34%	-	-	-
D&A For EBITDA	4.81	5.97	6.41	6.34	7.03
EBIT	-74.88	-97.98	-165.4	-175.58	-132.23
EBIT Margin	-50.14%	-90.88%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.